Capricor Therapeutics Inc (OTCMKTS:CAPR) has been assigned a $2.00 price objective by equities research analysts at HC Wainwright in a report released on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 192.01% from the company’s previous close.
CAPR has been the topic of several other research reports. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Monday, April 17th. ValuEngine cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Capricor Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $7.88.
Capricor Therapeutics (CAPR) traded up 98.57% during midday trading on Tuesday, reaching $1.36. 28,676,696 shares of the company traded hands. Capricor Therapeutics has a 12-month low of $0.63 and a 12-month high of $4.44. The company’s market cap is $30.73 million. The company has a 50-day moving average price of $0.88 and a 200-day moving average price of $2.34.
Capricor Therapeutics (OTCMKTS:CAPR) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. The firm had revenue of $0.88 million during the quarter, compared to the consensus estimate of $0.87 million. On average, analysts predict that Capricor Therapeutics will post ($0.74) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/07/18/hc-wainwright-analysts-give-capricor-therapeutics-inc-otcmktscapr-a-2-00-price-target.html.
In related news, Director Louis Manzo bought 10,000 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were purchased at an average price of $3.10 per share, with a total value of $31,000.00. Following the completion of the purchase, the director now owns 138,384 shares of the company’s stock, valued at approximately $428,990.40. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Sinai Medical Center Cedars bought 1,145,161 shares of the business’s stock in a transaction on Tuesday, May 9th. The stock was bought at an average cost of $3.10 per share, for a total transaction of $3,549,999.10. Following the purchase, the insider now directly owns 4,049,959 shares of the company’s stock, valued at approximately $12,554,872.90. The disclosure for this purchase can be found here.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
